Zocco 2003.

Study characteristics
Methods	RCT (abstract only) Setting: not stated Study period: not stated
Participants	Inclusion: inactive UC and quiescent Crohn's disease* Exclusion: not stated Age (mean): 32 years Sex (M/F): 20/16 Site of disease: not stated Use of medication: not stated Length of time remission at study entry: not stated Number randomised (n = 36): 12 (probiotic)/10 (mesalazine)/14 (probiotic + mesalazine) Number assessed: 12 (probiotic)/10 (mesalazine)/14 (probiotic + mesalazine) Postrandomisation exclusion: none
Interventions	Probiotic alone: Lactobacillus GG 18 X 109 viable bacteria per day (Giflorex, Errekappa, Euroterapic, SpA, Milan, Italy) Probiotic + mesalazine: Lactobacillus GG 18 X 109 viable bacteria and mesalazine 2.4 g per day Mesalazine 2.4 g per day
Outcomes	Duration of follow‐up: 12 months Relapse (defined by clinical and endoscopic features. No further details) Withdrawal due to adverse events
Notes	Funding source: not stated Declaration of interest: not reported Data from participants with CD were discarded due to the limited scope of the review.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Participants were reportedly randomised, however, no further details were available
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not stated
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not stated
Incomplete outcome data (attrition bias) All outcomes	Low risk	All participants appear to have been accounted for
Selective reporting (reporting bias)	Unclear risk	The study was published as an abstract. Insufficient information to make a judgement
Other bias	Unclear risk	The study was published as an abstract. Insufficient information to make a judgement